Development↦Ethics and Laws↦Federal Office of Public Health Application↦Submission
What is it? Why is it important?
For the approval of some studies, Swissmedic and the Ethics Committee (EC) seek the opinion of the Federal Office of Public Health (FOPH).
Swissmedic seeks the opinion of the FOPH in:
- Studies on gene therapy and genetically modified pathogenic organisms (risk-categories B and C)
- IMP / MD combination (in vitro) studies capable of emitting ionising radiation (risk-category C)
- Studies using a radiation source exceeding 5mSv per year for participants (risk-category C)
The EC seeks the opinion of the FOPH in:
- Studies in transplantation of human organs, tissues and cells (risk-category C)
- Studies using a radiation source exceeding 5mSv per year for participants (risk-category C)
Regarding studies of gene therapy and genetically modified / pathogenic organisms, Swissmedic together with the FOPH and the FOEN jointly issue guidelines on risks to human health and the environment.
What do I need to do?
As a SP-INV, submit the following studies for approval to the FOPH:
- Risk-category C studies with the transplantation of human organs, tissues and cells
- Studies with a radiopharmaceutical (medicinal product) that is:
- Not used in accordance with the authorisation; or
- Not authorised in Switzerland
- Studies with a medical device capable of emitting ionising radiation:
- Not used in accordance with the instructions for use; or
- Does not have a conformity marking; or
- Uses some other radioactive source
For Category C studies, the application must be submitted to the second authority within two years after approval has been granted by the first authority.
Category C studies are submitted both to EC and to Swissmedic. Submissions can be done in parallel.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
FOPH – see in particular tabs
- Medicine & research / Research involving humans
- Medicine & research / Research involving human embryonic stem cells
- Laws & Licenses / Applications & Approvals / Biosafety: notifications & authorisations
- Laws & Licenses / Applications & Approvals / Exemption authorisations and authorisations banned narcotics
FOEN - Approval regarding environmental concerns
Swiss Law
ClinO – see in particular articles and annexes
- Art. 35 Procedure for gene therapy and genetically modified pathogenic organism
- Art. 36 Procedure for IMP capable of emitting ionising radiation
- Art. 36a Procedure for accompanying examinations involving ionising radiation
- Art. 50 Coordination in authorisation procedures for organ, tissue or cells transplantation
- Art. 52 Exemption from mandatory authorisation for organ, tissue or cells transplantation
- Annex 3 Submission requirements for investigation with radiation sources
- Annex 4 Submission requirements for transplantation, gene therapy, genetically modified/pathogenic organism
ClinO-MD – see in particular articles and annex
- Art. 14 Procedure for accompanying examinations involving ionising radiation
- Art. 18 Trials with MD capable of emitting ionising radiation
- Art. 36a Procedure for accompanying examinations involving ionising radiation
- Annex 1 Submission document list
HRO – see in particular article and annex
- Art. 19 Procedure for accompanying examinations involving ionising radiation
- Annex 2 Submission document list